Biofeedback Therapy in the Treatment of Children With Dysfunctional Voiding: Does the Presence of Overactive Bladder Affect Treatment Outcomes?

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology Pub Date : 2025-07-01 DOI:10.1111/iju.70171

Furkan Adem Canbaz, Gonca Gerçel, Gülce Kadakal Köken, Sefa Sağ

{"title":"Biofeedback Therapy in the Treatment of Children With Dysfunctional Voiding: Does the Presence of Overactive Bladder Affect Treatment Outcomes?","authors":"Furkan Adem Canbaz, Gonca Gerçel, Gülce Kadakal Köken, Sefa Sağ","doi":"10.1111/iju.70171","DOIUrl":null,"url":null,"abstract":"Objectives: This study evaluated biofeedback therapy for treating dysfunctional voiding (DV) and examined how overactive bladder (OAB) affects treatment outcomes.Methods: Files of children treated with biofeedback therapy for DV between November 2022-November 2023 were retrospectively analyzed. Data collected included demographics, clinical information, dysfunctional voiding symptom scores (DVSS), and uroflowmetry (UF) parameters. Patients were categorized into two groups: Group 1 (DV with OAB) and Group 2 (DV without OAB). Clinical success meant cessation of electromyography (EMG) activity, resolution of symptoms, and improved UF parameters. Treatment outcomes were evaluated using the International Children's Continence Society recommendations.Results: The study comprised 32 children: 15 in Group 1 (11 girls, 4 boys; mean age: 8.7 ± 3.7 years) and 17 in Group 2 (15 girls, 2 boys; mean age: 7.7 ± 1.9 years). The overall complete response rate was 65.6% (n = 21), and the partial response rate was 21.9% (n = 7). Success rates of Group 1 and Group 2 were similar (complete response: 60.0% vs. 70.6%, p > 0.05; partial response: 20.0% vs. 23.5%, p > 0.05). Both groups showed significant DVSS reduction (p < 0.05). EMG cessation occurred in 84.4% of patients. Postvoid residual volume (%) decreased significantly in Group 2 (p = 0.002) but not in Group 1 (p > 0.05).Conclusions: Biofeedback therapy effectively treats DV, with OAB presence not impacting treatment success.Trial registration: UMIN000055031.","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/iju.70171","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study evaluated biofeedback therapy for treating dysfunctional voiding (DV) and examined how overactive bladder (OAB) affects treatment outcomes.

Methods: Files of children treated with biofeedback therapy for DV between November 2022-November 2023 were retrospectively analyzed. Data collected included demographics, clinical information, dysfunctional voiding symptom scores (DVSS), and uroflowmetry (UF) parameters. Patients were categorized into two groups: Group 1 (DV with OAB) and Group 2 (DV without OAB). Clinical success meant cessation of electromyography (EMG) activity, resolution of symptoms, and improved UF parameters. Treatment outcomes were evaluated using the International Children's Continence Society recommendations.

Results: The study comprised 32 children: 15 in Group 1 (11 girls, 4 boys; mean age: 8.7 ± 3.7 years) and 17 in Group 2 (15 girls, 2 boys; mean age: 7.7 ± 1.9 years). The overall complete response rate was 65.6% (n = 21), and the partial response rate was 21.9% (n = 7). Success rates of Group 1 and Group 2 were similar (complete response: 60.0% vs. 70.6%, p > 0.05; partial response: 20.0% vs. 23.5%, p > 0.05). Both groups showed significant DVSS reduction (p < 0.05). EMG cessation occurred in 84.4% of patients. Postvoid residual volume (%) decreased significantly in Group 2 (p = 0.002) but not in Group 1 (p > 0.05).

Conclusions: Biofeedback therapy effectively treats DV, with OAB presence not impacting treatment success.

Trial registration: UMIN000055031.

查看原文本刊更多论文

生物反馈疗法治疗儿童排尿功能障碍：膀胱过度活动是否影响治疗结果？

目的：本研究评估生物反馈疗法治疗功能障碍排尿（DV），并检查膀胱过动症（OAB）如何影响治疗结果。方法：回顾性分析2022年11月至2023年11月间接受DV生物反馈治疗的患儿档案。收集的数据包括人口统计学、临床信息、功能障碍排尿症状评分（DVSS）和尿流仪（UF）参数。患者分为两组：1组（DV合并OAB）和2组（DV无OAB）。临床成功意味着肌电图（EMG）活动的停止，症状的缓解和UF参数的改善。根据国际儿童自制协会的建议评估治疗结果。结果：本研究共纳入32例儿童：第一组15例(女生11例，男生4例；平均年龄：8.7±3.7岁)，第二组17岁(女孩15例，男孩2例；平均年龄：7.7±1.9岁)。总完全缓解率为65.6% (n = 21)，部分缓解率为21.9% （n = 7）。组1和组2的成功率相似(完全缓解：60.0% vs. 70.6%, p < 0.05；部分缓解：20.0% vs. 23.5%, p < 0.05)。两组DVSS均显著降低（p < 0.05）。结论：生物反馈疗法有效治疗DV， OAB的存在不影响治疗成功。试验注册号：UMIN000055031。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Urology 医学-泌尿学与肾脏学

CiteScore

4.70

自引率

11.50%

发文量

340

审稿时长

3 months

期刊介绍： International Journal of Urology is the official English language journal of the Japanese Urological Association, publishing articles of scientific excellence in urology. Submissions of papers from all countries are considered for publication. All manuscripts are subject to peer review and are judged on the basis of their contribution of original data and ideas or interpretation.